Capital Advisors Inc. OK Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Advisors Inc. OK raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 310,270 shares of the company’s stock after buying an additional 9,681 shares during the period. Capital Advisors Inc. OK owned approximately 0.36% of CRISPR Therapeutics worth $12,212,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC raised its stake in shares of CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. Tyche Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $328,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management raised its stake in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of CRISPR Therapeutics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,098 shares of the company’s stock valued at $712,000 after purchasing an additional 1,717 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CRSP shares. HC Wainwright started coverage on shares of CRISPR Therapeutics in a research note on Monday, February 3rd. They set a “buy” rating and a $65.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Stock Up 0.5 %

Shares of CRSP stock opened at $39.62 on Wednesday. The firm has a fifty day moving average of $42.45 and a 200-day moving average of $46.40. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.